P-选择蛋白用于诊断肾移植术后排异的可行性探讨

Feasibility of using the level of GMP-140 in diagnosing renal transplantation rejection

目的:寻找一个比环孢素A(CsA)更加灵敏的、经济的、用于诊断肾移植(RT)术后排异反应的特异性指标。方法:采用酶联免疫吸附法(ELISA)测定血浆P-选择蛋白水平,采用单克隆抗体荧光偏振免疫分析法(FPIA)测定CsA谷浓度,分析了P-选择蛋白的变化与CsA谷浓度、疗效三者之间的相关性,并对二者诊断RT术后的准确性进行了比较,探讨了P-选择蛋白用于诊断RT术后排异的可行性。结果:当移植肾有发生排异的趋势时,血浆P-选择蛋白会有显著增高,且其用于诊断RT术后排异的准确率明显大于CsA(P<0.05)。结论:P-选择蛋白可以作为一个更加灵敏的、用于诊断排异反应的特异性指标。

OBJECTIVE To find a sensitive, economical and specific index better than CsA for diagnosing rejection in early stage, METHODS GMP-140 in plasma was determined by ELISA method, while the minimal concentration of CsA was monitored by FPIA method. The relationship among them and curative effect was analyzed, at mean time, the accuracy of diagnosing rejection with both CsA and GMP-140 index was compared, therefore, the feasibility of using GMP-140 in diagnosing renal transplantation rejection was studied. RESULTS When the rejection tendency is existed, the level of GMP-140 was significantly higher than that in the normal or nephrotoxicity group （P〈0.05）, and the accuracy of GMP-140 in diagnosing rejection was much better than CsA. CONCLUSION The level of GMP-140 in plasma can be used as a sensitive and specific index on diagnosing renal transplantation rejection in early stage